http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Ji Seok Kim ),( Chan Hee Nam ),( Ji Yeon Yoo1 ),( Hyun Jung Kim ),( Se Kyoo Jeong ),( Sung Ku Ahn ),( Seung Phil Hong ) 한국피부장벽학회 2014 한국피부장벽학회지 Vol.16 No.2
Purpose: There are researches indicating that in human skin, the cannabinoid receptors exist, which take a part of endocannabinoid system. Nonetheless, the possible association of cannabinoid receptors with the pathogenesis of psoriasis has not yet been fully elucidated. Through this research, we tried to document the association between cannabinoid system, epidermal differentiation and psoriasis. Methods: Using human keratinocyte (KC), the expression of cannabinoid receptor-1 (CB1R) and -2 (CB2R) was analyzed according to the degree of differentiation. Also we examined for changes in differentiation marker of KC after application of CBR agonist. In addition, murine model applied with imiquimod to induce psoriasis symptoms was used to evaluate the effect of topical CBR agonist on inflammation and skin barrier function. Results: Compared to normal human skin, CBR expression was reduced in epidermis of psoriasis skin. Western blotting revealed the expression of both CB1R and CB2R in undifferentiated KC. The expression level of CB1R increased as the differentiation progressed in KC as with involucrin, K1 and K10. On the other hand, there was no change of CB2R in the process of differentiation. Furthermore, CB1R agonist partly increased expression of proteins associated with epidermal differentiation. Through this we could speculate that the CB system may be associated with proteins related to epidermal differentiation. Moreover, inflammation and barrier function in murine models with psoriasis symptoms were improved after 3 days-application of topical CB1R agonist. Conclusion: Cannabinoid receptors in human skin might be related to the differentiation of KC, and since its activation could improve skin barrier condition in murine psoriasis model, it can be expected to be a new therapeutic target for treatment of psoriasis.
보문 : 버섯 세균성갈색무늬병원균(Pseudomonas tolaasii)의 분비 독소(tolaasin)를 저해하는 미생물 Pseudomonas sp. HC1
이찬중 ( Chan Jung Lee ),유영미 ( Young Mi Yoo ),한주연 ( Ju Yeon Han ),전창성 ( Chang Sung Jhune ),정종천 ( Jong Chun Cheong ),문지원 ( Ji Won Moon ),서장선 ( Jang Sun Suh ),한혜수 ( Hye Su Han1 ),차재순 ( Jae Soon Cha ) 한국균학회 2013 韓國菌學會誌 Vol.41 No.4
A Gram-negative bacterium was isolated from mushroom media that markedly reduces the level of extracellular toxins (i.e., tolaasins) produced by Pseudomonas tolaasii, the most destructive pathogen of cultivated mushrooms. The HC1 strain was selected as detoxifying tolaasin by bioassay on potato and it was identified Pseudomonas sp. by the cultural, morphological and physiological characteristics, and analysis of the 16S rRNA.. The isolated bacterium is saprophytic but not parasitic nor pathogenic to cultivation mushroom. The isolated bacterium for P. tolaasii cell, was sufficient for detoxification in vitro. Inoculation of the isolated bacterium prevents the development of bacterial disease in Pleurotus ostreatus, Flammunia velutipes and Agaricus bisporus. Control efficacy of brown blotch of strain HC1 treatment was 69, 68 and 55% on Agaricus bisporus, Flammulina velutipes and Pleurotus ostreatus, respectively. The suppressive bacterium may be useful in future for the development of biocontrol system and the construction of genetically modified edible fungi resistant to the disease caused by P. tolaasii.